Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 7Gastrointestinal 3Dermatologic 3Breast 3Thoracic 2Genitourinary 2Sarcoma 1Plasma cell 1

Conditions

Neoplasms, Plasma Cell 3Urinary Bladder Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma 1Ovarian Neoplasms 1Melanoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Cyclophosphamide 6fludarabine 4Magnetic Resonance Spectroscopy 3Flow Cytometry 3trametinib 2pembrolizumab 2liposomal doxorubicin 2dabrafenib 2aldesleukin 2Specimen Handling 2Methylprednisolone 2Immunologic Techniques 2Gemcitabine 2Dexamethasone 2Biopsy 2Azacitidine 2Alemtuzumab 2ulixertinib 1trastuzumab biosimilar HLX02 1sargramostim 1saracatinib 1sapanisertib 1ruxolitinib 1rucaparib 1resiquimod 1relatlimab 1poly ICLC 1pertuzumab 1palbociclib 1osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × poly ICLC × Plasma cell × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡